A number of other equities analysts also recently commented on the stock. UBS set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Wednesday, March 14th. Kepler Capital Markets set a €106.00 ($130.86) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Monday, March 12th. DZ Bank restated a buy rating on shares of Merck KGaA in a research note on Monday, March 12th. Nord/LB set a €84.00 ($103.70) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research note on Monday, March 12th. Finally, Cfra set a €85.00 ($104.94) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research note on Friday, March 9th. Twelve analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Merck KGaA has a consensus rating of Hold and a consensus target price of €100.55 ($124.13).
Merck KGaA stock opened at €76.16 ($94.02) on Monday. Merck KGaA has a one year low of €76.60 ($94.57) and a one year high of €115.00 ($141.98). The company has a market cap of $10,070.00 and a PE ratio of 12.74.
WARNING: “Berenberg Bank Analysts Give Merck KGaA (MRK) a €106.00 Price Target” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://ledgergazette.com/2018/03/23/berenberg-bank-analysts-give-merck-kgaa-mrk-a-106-00-price-target.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.